Gabather AB (publ) (STO:GABA)

Market Cap	17.99M +440.0%
Revenue (ttm)	n/a
Net Income	-4.75M
EPS	-0.04
Shares Out	491.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,718,431
Average Volume	1,305,228
Open	0.0320
Previous Close	0.0328
Day's Range	0.0318 - 0.0368
52-Week Range	0.0230 - 0.1300
Beta	-0.47
RSI	59.09
Earnings Date	Feb 6, 2026

About Gabather AB

Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer’s disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer’s disease, schizophrenia, and major depressive disorders. The company was incorporated in 2014 and is based in Södertälje, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 3
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GABA